<DOC>
	<DOCNO>NCT02957409</DOCNO>
	<brief_summary>The purpose study describe heart failure reduce ejection fraction ( HFrEF ) patient population receive sacubitril/valsartan treatment .</brief_summary>
	<brief_title>PAtient RegisTry Assessing Effectiveness Safety HEart Failure treatmeNt With LCZ696 acrOss CaNada</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Receiving sacubitril/valsartan per Canadian product label treatment initiation within last 3 month Able communicate investigator Participation clinical trial investigational drug , concurrently , within last 30 day Presence condition opinion investigator , prohibit patient participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Heart Failure Reduced Ejection Fraction</keyword>
	<keyword>HFrEF</keyword>
</DOC>